表纸
市场调查报告书

肿瘤浸润性淋巴球 (TIL):癌症免疫疗法新的国境

Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy

出版商 BCC Research 商品编码 882253
出版日期 内容资讯 英文 21 Pages
订单完成后即时交付
价格
Back to Top
肿瘤浸润性淋巴球 (TIL):癌症免疫疗法新的国境 Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
出版日期: 2019年07月03日内容资讯: 英文 21 Pages
简介

本报告提供癌症免疫疗法新的国境的肿瘤浸润性淋巴球 (TIL)的R&D趋势调查,肿瘤浸润性淋巴球 (TIL)的概要,转移性黑色素瘤、其他肿瘤的TIL治疗药的开发趋势,主要企业、研究中心的临床开发趋势等汇整资料。

第1章 使用了TIL的细胞治疗的出现

第2章 转移性黑色素瘤的TIL治疗药的开发

  • TIL的发生
  • 淋巴球干涸的重要性
  • 白细胞介素2所扮演的角色
  • 作为主流的治疗选择的TIL的可行性

第3章 其他肿瘤类型中TIL治疗药的开发

  • 子宫颈癌
  • 卵巢癌
  • 肾脏癌
  • 消化道恶性肿瘤
  • 头颈椎癌症

第4章 TIL治疗药临床开发

  • Lifileucel (LN-144):Iovance Biotherapeutics
  • LN-145:Iovance Biotherapeutics
  • TILT-123:TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • 其他TIL研究中心
  • 未来展望

第5章 文献

目录
Product Code: BIO129A

Report Highlights:

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

Report Includes:

  • An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer
  • Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
  • Exploration of adoptive T-cell therapy (ATCT) using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, and the curative potential of ATCT in a variety of other solid tumors
  • Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
  • Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications

Table of Contents

Chapter 1: The Emergence of Cell Therapy Using TILs

  • Introduction
  • Analyst's Credentials
  • Related Reports

Chapter 2: Development of TIL Therapies in Metastic Melanoma

  • TIL Generation Explained
  • Importance of Lymphodepletion
  • Role of Interleukin-2
  • Feasibility of TIL as a Mainstream Treatment Option

Chapter 3: Development of TIL Therapies in Other Tumour Types

  • Cervical Cancer
  • Ovarian Cancer
  • Kidney Cancer
  • Gastrointestinal Cancer
  • Head and Neck Cancers

Chapter 4: Clinical Development of TIL Therapies

  • Lifileucel (LN-144), Iovance Biotherapeutics
  • LN-145, Iovance Biotherapeutics
  • TILT-123, TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • Other Centers Conducting TIL Research
  • Future Perspectives for TIL

Chapter 5: References

List of Tables

  • Table 1: TILs and Tumor Specific Antigens
  • Table 2: Adoptive T-Cell Therapy (ATC) Cellular Therapies
  • Table 3: Clinical Trials Studying TIL Therapies

List of Figures

  • Figure 1: Generation of Tumor Infiltrating Lymphocytes
  • Figure 2: IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types
  • Figure 3: TILT Biotherapeutics Development Pipeline
Back to Top